BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bi J, Lau SH, Lv ZL, Xie D, Li W, Lai YR, Zhong JM, Wu HQ, Su Q, He YL. Overexpression of YKL-40 is an independent prognostic marker in gastric cancer. Hum Pathol. 2009;40:1790-1797. [PMID: 19765801 DOI: 10.1016/j.humpath.2009.07.005] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 2.8] [Reference Citation Analysis]
Number Citing Articles
1 Yasar O, Akcay T, Obek C, Turegun FA. Diagnostic potential of YKL-40 in bladder cancer. Urologic Oncology: Seminars and Original Investigations 2016;34:257.e19-24. [DOI: 10.1016/j.urolonc.2016.02.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
2 Ng L, Poon RTP, Pang R. Biomarkers for predicting future metastasis of human gastrointestinal tumors. Cell Mol Life Sci 2013;70:3631-56. [DOI: 10.1007/s00018-013-1266-8] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 2.3] [Reference Citation Analysis]
3 Prakash M, Bodas M, Prakash D, Nawani N, Khetmalas M, Mandal A, Eriksson C. Diverse pathological implications of YKL-40: Answers may lie in ‘outside-in’ signaling. Cellular Signalling 2013;25:1567-73. [DOI: 10.1016/j.cellsig.2013.03.016] [Cited by in Crossref: 53] [Cited by in F6Publishing: 55] [Article Influence: 5.9] [Reference Citation Analysis]
4 Radchenko VV, Il'nitskaia EV, Tret'iakov VE, Serebriakova MV, Storozheva ZI, Shuvaeva TM, Lipkin VM. [Identification in the rat olfactory epithelium new subgroup YM-1 chitinase-like protein]. Bioorg Khim 2010;36:646-53. [PMID: 21063451 DOI: 10.1134/s1068162010050079] [Reference Citation Analysis]
5 Marimuthu A, Subbannayya Y, Sahasrabuddhe NA, Balakrishnan L, Syed N, Sekhar NR, Katte TV, Pinto SM, Srikanth SM, Kumar P. SILAC-based quantitative proteomic analysis of gastric cancer secretome. Proteomics Clin Appl. 2013;7:355-366. [PMID: 23161554 DOI: 10.1002/prca.201200069] [Cited by in Crossref: 40] [Cited by in F6Publishing: 39] [Article Influence: 4.4] [Reference Citation Analysis]
6 Wang D, Lu JG, Wang Q, Du XL, Dong R, Wang P, Zhao L, Jiang X, Yuan LJ. Increased immunohistochemical expression of YKL-40 in the spleen of patients with portal hypertension. Braz J Med Biol Res 2012;45:264-72. [PMID: 22267006 DOI: 10.1590/s0100-879x2012007500010] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 0.9] [Reference Citation Analysis]
7 Liu L, Yang Y, Duan H, He J, Sun L, Hu W, Zeng J. CHI3L2 Is a Novel Prognostic Biomarker and Correlated With Immune Infiltrates in Gliomas. Front Oncol 2021;11:611038. [PMID: 33937022 DOI: 10.3389/fonc.2021.611038] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
8 Yang JD, Kim E, Pedersen RA, Kim WR, Pungpapong S, Roberts LR. Utility of Serum YKL-40 as a Tumor-Specific Marker of Hepatobiliary Malignancies. Gut Liver 2010;4:537-42. [PMID: 21253305 DOI: 10.5009/gnl.2010.4.4.537] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
9 Geng B, Pan J, Zhao T, Ji J, Zhang C, Che Y, Yang J, Shi H, Li J, Zhou H, Mu X, Xu C, Wang C, Xu Y, Liu Z, Wen H, You Q. Chitinase 3-like 1-CD44 interaction promotes metastasis and epithelial-to-mesenchymal transition through β-catenin/Erk/Akt signaling in gastric cancer. J Exp Clin Cancer Res 2018;37:208. [PMID: 30165890 DOI: 10.1186/s13046-018-0876-2] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 7.8] [Reference Citation Analysis]
10 Peng C, Peng J, Jiang L, You Q, Zheng J, Ning X. YKL-40 protein levels and clinical outcome of human endometrial cancer. J Int Med Res 2010;38:1448-57. [PMID: 20926018 DOI: 10.1177/147323001003800427] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
11 Tschirdewahn S, Reis H, Niedworok C, Nyirady P, Szendröi A, Schmid KW, Shariat SF, Kramer G, vom Dorp F, Rübben H, Szarvas T. Prognostic effect of serum and tissue YKL-40 levels in bladder cancer. Urologic Oncology: Seminars and Original Investigations 2014;32:663-9. [DOI: 10.1016/j.urolonc.2014.02.004] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
12 Harving ML, Christensen LH, Ringsholt M, Lausten GS, Petersen MM. YKL-40 expression in soft-tissue sarcomas and atypical lipomatous tumors. An immunohistochemical study of 49 tumors. Acta Orthop 2014;85:195-200. [PMID: 24650028 DOI: 10.3109/17453674.2014.893496] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
13 Cantó E, Tintoré M, Villar LM, Costa C, Nurtdinov R, Álvarez-cermeño JC, Arrambide G, Reverter F, Deisenhammer F, Hegen H, Khademi M, Olsson T, Tumani H, Rodríguez-martín E, Piehl F, Bartos A, Zimova D, Kotoucova J, Kuhle J, Kappos L, García-merino JA, Sánchez AJ, Saiz A, Blanco Y, Hintzen R, Jafari N, Brassat D, Lauda F, Roesler R, Rejdak K, Papuc E, de Andrés C, Rauch S, Khalil M, Enzinger C, Galimberti D, Scarpini E, Teunissen C, Sánchez A, Rovira A, Montalban X, Comabella M. Chitinase 3-like 1: prognostic biomarker in clinically isolated syndromes. Brain 2015;138:918-31. [DOI: 10.1093/brain/awv017] [Cited by in Crossref: 97] [Cited by in F6Publishing: 90] [Article Influence: 13.9] [Reference Citation Analysis]
14 Larionova I, Cherdyntseva N, Liu T, Patysheva M, Rakina M, Kzhyshkowska J. Interaction of tumor-associated macrophages and cancer chemotherapy. Oncoimmunology 2019;8:1596004. [PMID: 31143517 DOI: 10.1080/2162402X.2019.1596004] [Cited by in Crossref: 79] [Cited by in F6Publishing: 57] [Article Influence: 26.3] [Reference Citation Analysis]
15 Huang WS, Lin H, Yeh C, Chen L, Chou Y, Yang S, Liu Y. Correlation of Chitinase 3-Like 1 Single Nucleotide Polymorphisms with Hepatocellular Carcinoma in Taiwan. Int J Med Sci 2017;14:136-42. [DOI: 10.7150/ijms.17754] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
16 Oh IH, Pyo JS, Son BK. Prognostic Impact of YKL-40 Immunohistochemical Expression in Patients with Colorectal Cancer. Curr Oncol 2021;28:3139-49. [PMID: 34436040 DOI: 10.3390/curroncol28040274] [Reference Citation Analysis]
17 Zhang SS, Wu LH, Liu Q, Chen KS, Zhang XF. Elevated expression of NEDD9 is associated with metastatic activity in gastric cancer. Onco Targets Ther 2015;8:633-40. [PMID: 25792847 DOI: 10.2147/OTT.S77904] [Cited by in Crossref: 17] [Cited by in F6Publishing: 8] [Article Influence: 2.4] [Reference Citation Analysis]
18 Zheng X, Xing S, Liu XM, Liu W, Liu D, Chi PD, Chen H, Dai SQ, Zhong Q, Zeng MS. Establishment of using serum YKL-40 and SCCA in combination for the diagnosis of patients with esophageal squamous cell carcinoma. BMC Cancer. 2014;14:490. [PMID: 25001061 DOI: 10.1186/1471-2407-14-490] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 2.8] [Reference Citation Analysis]
19 Pan JJ, Ge YS, Xu GL, Jia WD, Liu WF, Li JS, Liu WB. The expression of chitinase 3-like 1: a novel prognostic predictor for hepatocellular carcinoma. J Cancer Res Clin Oncol. 2013;139:1043-1054. [PMID: 23525579 DOI: 10.1007/s00432-013-1415-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
20 Kastrup J. Can YKL-40 be a new inflammatory biomarker in cardiovascular disease? Immunobiology 2012;217:483-91. [DOI: 10.1016/j.imbio.2011.04.007] [Cited by in Crossref: 55] [Cited by in F6Publishing: 50] [Article Influence: 5.5] [Reference Citation Analysis]
21 Wang D, Zhai B, Hu F, Liu C, Zhao J, Xu J. High YKL-40 serum concentration is correlated with prognosis of Chinese patients with breast cancer. PLoS One 2012;7:e51127. [PMID: 23227243 DOI: 10.1371/journal.pone.0051127] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 2.1] [Reference Citation Analysis]
22 Xu CH, Yu LK, Hao KK. Serum YKL-40 level is associated with the chemotherapy response and prognosis of patients with small cell lung cancer. PLoS One 2014;9:e96384. [PMID: 24801872 DOI: 10.1371/journal.pone.0096384] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
23 de Bree E, Charalampakis V, Melissas J, Tsiftsis DD. The extent of lymph node dissection for gastric cancer: a critical appraisal. J Surg Oncol. 2010;102:552-562. [PMID: 20976727 DOI: 10.1002/jso.21646] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
24 Min L, Zhu S, Wei R, Zhao Y, Liu S, Li P, Zhang S. Integrating SWATH-MS Proteomics and Transcriptome Analysis Identifies CHI3L1 as a Plasma Biomarker for Early Gastric Cancer. Mol Ther Oncolytics 2020;17:257-66. [PMID: 32346614 DOI: 10.1016/j.omto.2020.03.020] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
25 Schultz NA, Johansen JS. YKL-40-A Protein in the Field of Translational Medicine: A Role as a Biomarker in Cancer Patients? Cancers (Basel) 2010;2:1453-91. [PMID: 24281168 DOI: 10.3390/cancers2031453] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 3.3] [Reference Citation Analysis]
26 Shantha Kumara HMC, Gaita D, Miyagaki H, Yan X, Hearth SA, Njoh L, Cekic V, Whelan RL. Plasma chitinase 3-like 1 is persistently elevated during first month after minimally invasive colorectal cancer resection. World J Gastrointest Oncol 2016; 8(8): 607-614 [PMID: 27574553 DOI: 10.4251/wjgo.v8.i8.607] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
27 Zhang Q, Wang H, Ma Y, Zhang J, He X, Ma J, Zhao ZS. Overexpression of Nedd9 is a prognostic marker of human gastric cancer. Med Oncol 2014;31:33. [PMID: 24906654 DOI: 10.1007/s12032-014-0033-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
28 Zhang Q, Ye Z, Yang Q, He X, Wang H, Zhao Z. Upregulated expression of annexin II is a prognostic marker for patients with gastric cancer. World J Surg Oncol. 2012;10:103. [PMID: 22681645 DOI: 10.1186/1477-7819-10-103] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 2.5] [Reference Citation Analysis]
29 Li TM, Liu SC, Huang YH, Huang CC, Hsu CJ, Tsai CH, Wang SW, Tang CH. YKL-40-Induced Inhibition of miR-590-3p Promotes Interleukin-18 Expression and Angiogenesis of Endothelial Progenitor Cells. Int J Mol Sci 2017;18:E920. [PMID: 28448439 DOI: 10.3390/ijms18050920] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 4.4] [Reference Citation Analysis]
30 Mathiasen AB, Henningsen KMA, Harutyunyan MJ, Mygind ND, Kastrup J. YKL-40: a new biomarker in cardiovascular disease? Biomarkers in Medicine 2010;4:591-600. [DOI: 10.2217/bmm.10.58] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 1.7] [Reference Citation Analysis]
31 Fan JT, Si XH, Liao Y, Shen P. The diagnostic and prognostic value of serum YKL-40 in endometrial cancer. Arch Gynecol Obstet 2013;287:111-5. [PMID: 22945838 DOI: 10.1007/s00404-012-2546-5] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
32 Chen H, Zheng J, Zhang Y, Yang M, Wang Y, Man X, Chen Y, Cai Q, Li Z. Overexpression of YKL-40 Predicts Poor Prognosis in Patients Undergoing Curative Resection of Pancreatic Cancer. Pancreas 2017;46:323-34. [DOI: 10.1097/mpa.0000000000000751] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 2.2] [Reference Citation Analysis]
33 Thorn AP, Daugaard S, Christensen LH, Christensen IJ, Petersen MM. YKL-40 protein in osteosarcoma tumor tissue. APMIS 2016;124:453-61. [PMID: 26988273 DOI: 10.1111/apm.12524] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
34 Jian-bo X, Hui W, Yu-long H, Chang-hua Z, Long-juan Z, Shi-rong C, Wen-hua Z. Astrocyte-elevated gene-1 overexpression is associated with poor prognosis in gastric cancer. Med Oncol. 2011;28:455-462. [PMID: 20300973 DOI: 10.1007/s12032-010-9475-6] [Cited by in Crossref: 72] [Cited by in F6Publishing: 69] [Article Influence: 6.0] [Reference Citation Analysis]